While transcatheter aortic valve replacement (TAVR) has shown benefits, significant coronary artery disease affects 50% or more of patients who undergo such procedure. However, it is still unclear which is the best treatment strategy or how to handle this condition. Quantitative flow ratio (QFR) could be a non-invasive option to assess the severity of coronary<a href="https://solaci.org/en/2024/06/29/qfr-analysis-of-coronary-lesions-with-tavr/" title="Read more" >...</a>
When deciding on the optimal coronary artery revascularization treatment of coronary artery disease (CAD) patients, physicians normally assessed clinical presentation, surgical risk, survival expectation, and the likelihood of a better quality of life. Decisions are made after careful consideration, by the Heart Team, who will ponder options such as coronary artery bypass graft (CABG), percutaneous<a href="https://solaci.org/en/2024/06/26/events-in-cad-patients-who-refused-or-were-ineligible-for-cabg/" title="Read more" >...</a>
Achieving rapid and maximum inhibition of platelet aggregation can reduce complications related to scheduled percutaneous coronary intervention (PCI) in chronic coronary syndromes (CCS). Over the last few decades, the optimal timing for initiating P2Y12 inhibitors and their appropriate dosage have been the subject of numerous studies; however, they have not been clearly established yet. Higher<a href="https://solaci.org/en/2024/06/18/antiplatelet-treatment-with-ticagrelor-vs-clopidogrel-in-patients-with-chronic-coronary-syndrome/" title="Read more" >...</a>
Diabetic patients have twice as high a risk of developing coronary artery disease (CAD). Additionally, CAD increases mortality risk. Patients with a history of percutaneous coronary intervention (PCI) tend to need repeat revascularization, even with second generation stents. To date, there are few studies assessing the role of glycemic control in stent failure, stent thrombosis,<a href="https://solaci.org/en/2024/06/13/glycemic-control-and-coronary-stent-failure/" title="Read more" >...</a>
Drug-eluting balloons (DEB) with paclitaxel have shown efficacy and safety in the treatment of femoropopliteal disease. Sirolimus-eluting balloons (DEB S) are currently being introduced. This new drug acts during the cellular resting phase (G0) and is considered potentially more effective than paclitaxel, which is a cytostatic drug. However, there is no conclusive evidence in this<a href="https://solaci.org/en/2024/06/13/sirolimus-eluting-balloon-in-femoropopliteal-disease/" title="Read more" >...</a>
Multiple studies support the use of an early invasive approach in high risk patients with non-ST elevation acute coronary syndrome (NST ACS). This benefit of an invasive strategy over the expected management has been shown in randomized studies and meta-analysis. Patients with a history of cardiac artery bypass graft (CABG) represent approximately 10% of ACS<a href="https://solaci.org/en/2024/06/10/patients-with-cabg-history-and-new-n-st-acs-routine-invasive-strategy/" title="Read more" >...</a>
The retrograde technique has significantly improved the success of percutaneous treatment of chronic total occlusions (CTO). After crossing a collateral channel, creating a connection between the anterograde and retrograde systems is key. The most common technique for this is reverse controlled antegrade and retrograde subintimal tracking (reverse CART). This technique involves inflating a balloon over<a href="https://solaci.org/en/2024/05/31/cart-technique-for-chronic-total-occlusions/" title="Read more" >...</a>
Complete revascularization has shown in several studies and meta-analysis a benefit in mortality vs. incomplete revascularization. The REVIVED-BCIS looked at whether there were differences in mortality and hospitalization for cardiac failure in patients with ventricular function deterioration and viability when comparing coronary angioplasty(PCI) against optimal medical treatment. This study showed that PCI was not associated<a href="https://solaci.org/en/2024/05/17/europcr-2024-complete-revascularization-affects-clinical-outcomes-revived-bcis2-insights/" title="Read more" >...</a>
Despite primary angioplasty, many patients with ST elevation acute myocardial infarction with (STEMI) show evidence of microvascular dysfunction. This dysfunction can be characterized by two main factors: A new specific index has recently been identified to assess microcirculation called microvascular resistance reserve (MRR), which allows measuring vasodilatory capacity independent of the epicardium. The purpose of<a href="https://solaci.org/en/2024/05/17/europcr-2024-prognostic-value-of-mrr-in-stemi-group-analysis-of-individual-patients/" title="Read more" >...</a>
Bicuspid aortic valve (BAV) disease affects 1%-2% of the population and manifests with severe aortic stenosis in the middle-aged. It characterizes for a very different anatomy with more calcification than the tricuspid aortic valve. At present, surgical aortic valve replacement (SAVR) is the first treatment indication. TAVR in this scenario has shown, in different studies,<a href="https://solaci.org/en/2024/05/07/tavr-in-bicuspid-valves/" title="Read more" >...</a>